Clinical Trial: Carboplatin Periocular Injection for Retinoblastoma
Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Carboplatin in Subjects With
Brief Summary: This study will evaluate the clinical efficacy of periocular injections of carboplatin together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.
Detailed Summary: This study will be a phase Ⅲ open label interventional case series. Patients with retinoblastoma will be randomized to receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive carboplatin periocular on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 24 months .
Sponsor: Sun Yat-sen University
Current Primary Outcome: all cause mortality [ Time Frame: two years ]
Original Primary Outcome: Same as current
Current Secondary Outcome: side effects of carboplatin periocular injection in the Treatment of Retinoblastoma [ Time Frame: two years ]
Original Secondary Outcome: Same as current
Information By: Sun Yat-sen University
Dates:
Date Received: May 10, 2014
Date Started: January 2006
Date Completion: December 2015
Last Updated: December 18, 2014
Last Verified: August 2014